查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1462671

静脉血栓栓塞症治疗的全球市场预测（截至 2030 年）：按产品、疾病状态、最终用户和地区进行分析

Venous Thromboembolism Treatment Market Forecasts to 2030 - Global Analysis By Product, Disease Indication, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

2023年全球静脉血栓栓塞症治疗市场规模为12.8874亿美元，预计预测期内复合年增长率为10.7%，2030年达到26.2543亿美元。静脉血栓栓塞症(VTE) 治疗通常涉及多方面策略，以防止新血栓形成、降低併发症风险并促进血栓溶解。抗凝血剂经常用于即时治疗，以阻止血栓和栓塞的形成，因为它们可能导致危及生命的后果，例如肺动脉栓塞。血栓的治疗方法各不相同，并且根据血栓的位置和严重程度而有所不同，从口服抗凝血剂到静脉注射药物（如肝素）。

据美国心臟协会称，静脉血栓栓塞症(VTE) 是一项重大的公共卫生风险，仅在美国每年估计就有 60 万例病例。

提高对 VTE 的认识

由于医学教育、意识提升宣传活动和患者支持计划方面加大努力，静脉血栓栓塞症(VTE) 已被广泛认为是重要的医疗保健问题。识别 VTE 危险因子、症状和适当的诊断技术正在成为医疗保健专业培训的重要组成部分。此外，随着患者对 VTE 的了解越来越多，他们意识到早期介入并儘快就医的重要性。此外，医学协会和组织传播指南和建议支持宣传宣传活动，并确保 VTE 始终处于临床实践和公共卫生议程的前沿。

高昂的治疗费用

治疗 VTE 的相关费用，包括抗凝血剂、诊断测试、住院和治疗后护理，给患者、付款人和医疗保健系统带来了巨大的经济负担。儘管新型口服抗凝血剂（NOAC）比Warfarin需要更少的监测，但它们通常很昂贵，限制了它们的可用性，特别是在资源有限的环境中。此外，某些患者群体，例如患有高风险血栓性疾病或復发性静脉血栓栓塞的患者，需要更长时间持续抗凝血治疗，这进一步增加了治疗成本。

增加直接口服抗凝血剂（DOAC）的使用

直接凝血酶抑制剂和 Xa 因子抑制剂是市场上快速成长的直接口服抗凝血剂 (DOAC) 的两个例子。快速起效、可预测的药物动力学和降低药物交互作用的风险只是 DOAC 相对于传统抗凝血治疗的一些优势。随着更多临床资料证明 DOAC 在治疗急性 VTE、延长血栓预防和预防次发性VTE 的安全性和有效性，预计 DOAC 的使用将会增加。此外，正在进行的研究旨在透过改善给药方案、探索新的适应症和开发逆转剂来解决出血併发症，进一步提高 DOAC 治疗 VTE 的有效性。

抗药性增加

抗凝血治疗VTE的有效性因抗药性的出现而受到严重威胁。影响药物代谢的遗传变异、药物标靶的后天变异、不遵守治疗方法是导致抗凝血剂抗药性的一些因素。抗药性的产生会降低抗凝血剂的治疗效果，导致治疗失败并增加血栓事件的风险。此外，对于已经产生抗凝血抵抗的患者来说，缺乏替代治疗选择，使得充分治疗 VTE 变得更加困难。

COVID-19 的影响

静脉血栓栓塞症(VTE) 治疗市场动态受到 COVID-19 爆发的影响。儘管由于对严重COVID-19 病例血栓併发症的认识提高，抗凝血治疗的需求增加，但医疗服务、选择性手术和患者照护途径的变化正在导致 VTE 诊断和开始治疗延迟。 VTE 治疗的处方模式和市场动态也受到资源限制、供应链中断和不断变化的医疗保健优先事项的影响。此外，製药公司和静脉血栓栓塞治疗提供者还面临着大流行病经济影响带来的额外挑战，包括病患保险覆盖范围减少和医疗保健预算限制。

预计抗凝血剂领域在预测期内将是最大的

用抗凝血剂治疗静脉血栓栓塞症（VTE）的细分市场占据最大的市场占有率。抗凝血剂对于 VTE 的治疗至关重要，可预防血栓形成、栓塞和血栓事件復发。抗凝血剂有多种剂型，患者可以根据自身特征和临床需求选择治疗方法。此外，抗凝血剂包括肠胃外药物和口服药物。建议急性治疗 VTE，并透过抗凝血治疗长期预防血栓栓塞併发症。

预计门诊医疗中心细分市场在预测期内复合年增长率最高

当涉及静脉血栓栓塞症（VTE）治疗市场时，门诊医疗中心领域通常表现出最高的复合年增长率。门诊医疗中心提供各种医疗状况（包括 VTE）的诊断、治疗和管理的门诊服务。此外，向门诊护理的转变是由多种因素推动的，包括医疗成本的上涨、微创手术的发展以及优先考虑患者便利性和成本效益的基于价值的护理模式的采用。

占比最大的地区：

由于完善的医疗保健系统、高昂的医疗成本、先进的诊断工具以及肥胖、久坐的生活方式和人口老龄化等 VTE 危险因素的高患病率，北美地区占据了最大的份额。领先产业参与者的存在、持续的研发计划以及有利的报销做法进一步推动了北美市场的扩张。此外，在 VTE 的预防、诊断和治疗方面的积极努力，以及患者和医疗保健专业人员意识的提高，使该地区在 VTE 治疗市场上处于世界领先地位。

复合年增长率最高的地区：

欧洲是静脉血栓栓塞症（VTE）治疗市场复合年增长率最高的地区。许多因素导致了 VTE 病例的增长和发病率的增加，包括日益常见的危险因素，例如老化、肥胖和久坐的生活方式。此外，治疗方法、诊断方法和医疗基础设施的改进提高了我们控制 VTE 的能力。此外，强有力的研发努力、医疗改革和支持性法规结构正在促进创新并支持市场扩张。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球静脉血栓栓塞症治疗市场：副产品

  • 血栓清除装置
  • 下腔静脉滤器
    • 可回收过滤器
    • 永久过滤器
  • 丝袜
  • 抗凝血物
  • 压缩帮浦
  • 其他产品

第六章全球静脉血栓栓塞症治疗市场：依疾病状况

  • 深层静脉栓塞症
  • 肺动脉栓塞
  • 其他医疗状况

第七章全球静脉血栓栓塞症治疗市场：依最终使用者分类

  • 医院和诊所
  • 门诊治疗中心
  • 导管实验室
  • 其他最终用户

第八章全球静脉血栓栓塞症治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第九章 主要进展

  • 协议、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • Mitsubishi Tanabe Pharma Corporation
  • Cardinal Health, Inc.
  • Koninklijke Philips NV
  • Boston Scientific Corporation
  • Johnson & Johnson
  • Stryker Corporation
  • Sanofi
  • Abbott Laboratories
  • Leo Pharma A/S
  • Novartis AG
  • Pfizer Inc.
  • Mylan NV
  • Argon Medical Devices, Inc.
  • Medtronic plc
  • Teva Pharmaceutical Industries Ltd.
  • LifeTech Scientific Corporation
  • Bayer AG
  • CSL Limited
  • Biogenics Inc.
Product Code: SMRC25722

According to Stratistics MRC, the Global Venous Thromboembolism Treatment Market is accounted for $1288.74 million in 2023 and is expected to reach $2625.43 million by 2030 growing at a CAGR of 10.7% during the forecast period. In order to prevent new clot formation, lower the risk of complications, and encourage clot dissolution, venous thromboembolism (VTE) treatment usually entails a multifaceted strategy. Anticoagulant drugs, which can cause life-threatening outcomes like pulmonary embolism, are frequently used in immediate management to stop clot extension and embolization. Treatments for blood clots can vary, ranging from oral anticoagulants to intravenous drugs like heparin, depending on their location and severity.

According to the American Heart Association, venous thromboembolism (VTE) poses a significant risk to public health, with an estimated incidence of up to 600,000 cases per year in the United States alone.

Market Dynamics:

Driver:

Raising awareness of VTE

Venous thromboembolism (VTE) is now more widely acknowledged as a serious healthcare concern as a result of increased efforts in medical education, awareness campaigns, and patient advocacy programs. The identification of VTE risk factors, symptoms, and suitable diagnostic techniques is becoming a more important part of healthcare professionals training. Additionally, as patients gain more knowledge about VTE, they realize how critical it is to intervene early and seek medical attention as soon as possible. Further boosting awareness campaigns and guaranteeing that VTE stays a top concern in clinical practice and public health agendas is the distribution of guidelines and recommendations by medical societies and organizations.

Restraint:

Exorbitant treatment expenses

The expenses associated with treating VTE, such as anticoagulant drugs, diagnostic exams, hospital stays, and post-treatment care, can place a heavy financial strain on patients, insurers, and healthcare systems. Despite having fewer monitoring requirements than warfarin, novel oral anticoagulants (NOACs) are frequently more expensive, which limits their accessibility, particularly in settings with limited resources. Furthermore, treatment costs are further increased by the requirement for extended-duration anticoagulation therapy in specific patient populations, such as those with high-risk thrombophilic conditions or recurrent VTE.

Opportunity:

Increasing use of direct oral anticoagulants (DOACs)

Direct thrombin inhibitors and factor Xa inhibitors are two examples of direct oral anticoagulants (DOACs) that are seeing rapid growth in the market. The rapid onset of action, predictable pharmacokinetics, and reduced risk of drug interactions are just a few benefits that DOACs have over conventional anticoagulant therapies. It is anticipated that the use of DOACs will rise as more clinical data demonstrates their safety and effectiveness in treating acute VTE, prolonging thromboprophylaxis, and preventing secondary VTE. Additionally, ongoing studies aim to further improve the effectiveness of DOACs in the treatment of VTE by refining dosage regimens, investigating novel indications, and creating reversal medications to address bleeding complications.

Threat:

Rise in medication resistance

The efficacy of anticoagulant therapies in the treatment of VTE is seriously threatened by the emergence of drug resistance. Genetic variations affecting drug metabolism, acquired mutations in drug targets, and non-adherence to treatment regimens are some of the factors that can lead to resistance to anticoagulants. Resistance development could reduce anticoagulant drugs therapeutic effectiveness, which would result in treatment failure and a higher risk of thrombotic events. Moreover, the difficulty of adequately treating VTE is further compounded by the scarcity of alternative treatment options for patients who have developed anticoagulant resistance.

Covid-19 Impact:

Venous thromboembolism (VTE) treatment market dynamics have been affected by the COVID-19 pandemic. Delays in VTE diagnosis and treatment initiation have been caused by changes in healthcare delivery, elective procedures, and patient care pathways, even as the demand for anticoagulant therapies has increased due to the increased awareness of thrombotic complications in severe COVID-19 cases. The prescribing patterns and market dynamics for VTE treatments have also been impacted by resource limitations, disruptions in the supply chain, and changes in healthcare priorities. Additionally, pharmaceutical companies and providers of VTE treatment face additional challenges due to the economic effects of the pandemic, such as reduced patient insurance coverage and healthcare budget constraints.

The Anticoagulant Medications segment is expected to be the largest during the forecast period

The segment that treats venous thromboembolism (VTE) with anticoagulant medications holds the largest market share. In order to prevent clot formation, embolization, and recurrent thrombotic events, anticoagulants are essential to the management of VTE. Patients can choose their treatment according to their individual characteristics and clinical needs because these medications come in a variety of formulations. Furthermore, these include parenteral agents and oral anticoagulants. It is advised to treat VTE acutely and prevent thromboembolic complications over the long term with anticoagulant therapy.

The Ambulatory Care Centers segment is expected to have the highest CAGR during the forecast period

When it comes to the Venous Thromboembolism (VTE) Treatment Market, the ambulatory care center segment usually has the highest CAGR. Outpatient services for the diagnosis, treatment, and management of a range of medical conditions, including VTE, are provided by ambulatory care centers. Moreover, the growing inclination towards ambulatory care can be attributed to various factors, including rising healthcare costs, developments in minimally invasive procedures, and the adoption of value-based care models that prioritize patient convenience and cost effectiveness.

Region with largest share:

North America usually has the largest share, due to factors, like well-established healthcare system, high healthcare costs, sophisticated diagnostic tools, and a high prevalence of VTE risk factors like obesity, sedentary lifestyles, and aging populations, are responsible for this dominance. Further supporting the market expansion in North America is the existence of significant industry players, continuous R&D initiatives, and advantageous reimbursement practices. Additionally, due in part to the region's proactive approach to VTE prevention, diagnosis, and treatment, as well as rising patient and healthcare professional awareness, it leads the world in the VTE treatment market.

Region with highest CAGR:

Europe is the region that frequently exhibits the highest CAGR in the market for treatments for venous thromboembolism (VTE). A number of factors, including the aging population, obesity, and sedentary lifestyles, which are risk factors that are becoming more common, are responsible for this growth and the increased incidence of VTE cases. Furthermore, improvements in treatment modalities, diagnostic methods, and healthcare infrastructure improve the area's ability to control VTE. In addition, robust R&D efforts, healthcare reforms, and supportive regulatory frameworks encourage innovation and propel market expansion.

Key players in the market

Some of the key players in Venous Thromboembolism Treatment market include Mitsubishi Tanabe Pharma Corporation, Cardinal Health, Inc., Koninklijke Philips N.V., Boston Scientific Corporation, Johnson & Johnson, Stryker Corporation, Sanofi, Abbott Laboratories, Leo Pharma A/S, Novartis AG, Pfizer Inc., Mylan N.V., Argon Medical Devices, Inc., Medtronic plc, Teva Pharmaceutical Industries Ltd., LifeTech Scientific Corporation, Bayer AG, CSL Limited and Biogenics Inc.

Key Developments:

In January 2024, Cardinal Health Inc. announced an agreement to buy Specialty Networks for $1.2 billion in cash, as the drug distributor and medical products maker looks to enhance its data analytics capabilities. The company said the acquisition expands its offering in therapeutic areas and increases its data and research opportunities with biopharmaceutical manufacturers.

In January 2024, Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Axonics, Inc., a publicly traded medical technology company primarily focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. The purchase price is $71 in cash per share, reflecting an equity value of approximately $3.7 billion and an enterprise value of approximately $3.4 billion.

In January 2024, Johnson & Johnson has reached tentative agreement to resolve talc baby powder claims with more than 40 states, the world's biggest maker of health care products confirmed. That progress includes an agreement in principle that the company reached with a consortium of 43 State Attorneys Generals to resolve their talc claims.

Products Covered:

  • Thrombectomy Devices
  • Inferior Vena Cava Filters
  • Stockings
  • Anticoagulant Medications
  • Compression Pumps
  • Other Products

Disease Indications Covered:

  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Other Disease Indications

End Users Covered:

  • Hospitals and Clinics
  • Ambulatory Care Centers
  • Catheterization Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Venous Thromboembolism Treatment Market, By Product

  • 5.1 Introduction
  • 5.2 Thrombectomy Devices
  • 5.3 Inferior Vena Cava Filters
    • 5.3.1 Retrievable Filters
    • 5.3.2 Permanent Filters
  • 5.4 Stockings
  • 5.5 Anticoagulant Medications
  • 5.6 Compression Pumps
  • 5.7 Other Products

6 Global Venous Thromboembolism Treatment Market, By Disease Indication

  • 6.1 Introduction
  • 6.2 Deep Vein Thrombosis
  • 6.3 Pulmonary Embolism
  • 6.4 Other Disease Indications

7 Global Venous Thromboembolism Treatment Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals and Clinics
  • 7.3 Ambulatory Care Centers
  • 7.4 Catheterization Laboratories
  • 7.5 Other End Users

8 Global Venous Thromboembolism Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Mitsubishi Tanabe Pharma Corporation
  • 10.2 Cardinal Health, Inc.
  • 10.3 Koninklijke Philips N.V.
  • 10.4 Boston Scientific Corporation
  • 10.5 Johnson & Johnson
  • 10.6 Stryker Corporation
  • 10.7 Sanofi
  • 10.8 Abbott Laboratories
  • 10.9 Leo Pharma A/S
  • 10.10 Novartis AG
  • 10.11 Pfizer Inc.
  • 10.12 Mylan N.V.
  • 10.13 Argon Medical Devices, Inc.
  • 10.14 Medtronic plc
  • 10.15 Teva Pharmaceutical Industries Ltd.
  • 10.16 LifeTech Scientific Corporation
  • 10.17 Bayer AG
  • 10.18 CSL Limited
  • 10.19 Biogenics Inc.

List of Tables

  • Table 1 Global Venous Thromboembolism Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
  • Table 4 Global Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
  • Table 5 Global Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
  • Table 6 Global Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
  • Table 7 Global Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
  • Table 8 Global Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
  • Table 9 Global Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
  • Table 10 Global Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 11 Global Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 12 Global Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
  • Table 13 Global Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
  • Table 14 Global Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 15 Global Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 16 Global Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 17 Global Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 18 Global Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
  • Table 19 Global Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 20 North America Venous Thromboembolism Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 22 North America Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
  • Table 23 North America Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
  • Table 24 North America Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
  • Table 25 North America Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
  • Table 26 North America Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
  • Table 27 North America Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
  • Table 28 North America Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
  • Table 29 North America Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 30 North America Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 31 North America Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
  • Table 32 North America Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
  • Table 33 North America Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 34 North America Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 35 North America Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 36 North America Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 37 North America Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
  • Table 38 North America Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 39 Europe Venous Thromboembolism Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 41 Europe Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
  • Table 42 Europe Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
  • Table 43 Europe Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
  • Table 44 Europe Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
  • Table 45 Europe Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
  • Table 46 Europe Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
  • Table 47 Europe Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
  • Table 48 Europe Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 49 Europe Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 50 Europe Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
  • Table 51 Europe Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
  • Table 52 Europe Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 53 Europe Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 54 Europe Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 55 Europe Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 56 Europe Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
  • Table 57 Europe Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 58 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 60 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
  • Table 61 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
  • Table 62 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
  • Table 63 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
  • Table 64 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
  • Table 65 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
  • Table 66 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
  • Table 67 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 68 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 69 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
  • Table 70 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
  • Table 71 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 72 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 73 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 74 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 75 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
  • Table 76 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 77 South America Venous Thromboembolism Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 79 South America Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
  • Table 80 South America Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
  • Table 81 South America Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
  • Table 82 South America Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
  • Table 83 South America Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
  • Table 84 South America Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
  • Table 85 South America Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
  • Table 86 South America Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 87 South America Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 88 South America Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
  • Table 89 South America Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
  • Table 90 South America Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 91 South America Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 92 South America Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 93 South America Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 94 South America Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
  • Table 95 South America Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 96 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 98 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
  • Table 99 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
  • Table 100 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
  • Table 101 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
  • Table 102 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
  • Table 103 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
  • Table 104 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
  • Table 105 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 106 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 107 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
  • Table 108 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
  • Table 109 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 110 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 111 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 112 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 113 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
  • Table 114 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)